Growing Shareholder Value

Event Details

Q1 2021 Abiomed, Inc. Earnings Conference Call
Aug 6, 2020 at 8:00 AM EDT Aug 6, 2020
8:00 AM EDT
Webcast Presentation
Event Details
Title Q1 2021 Abiomed, Inc. Earnings Conference Call
Date and Time Aug 6, 2020 at 8:00 AM EDT Aug 6, 2020
8:00 AM EDT


The content of this webcast includes a discussion of Abiomed products that have not been approved or cleared by the United States Food and Drug Administration and are not available for sale in the United States. This presentation also discusses certain uncleared and unapproved uses of Abiomed products. This information is intended solely for purposes of informing the investment community, and not for any other purpose.

This presentation contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995 that involve substantial risks and uncertainties. All statements, other than statements of historical facts, are forward-looking statements. The words "anticipate," "believe," "estimate," "expect," "intend," "may," "plan," "predict," "project," "target," "potential," "will," "would," "could," "should," "continue," "contemplate," or the negative of these terms or other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. In addition, any statements that refer to projections regarding expectations of revenue, expenses, earnings or losses from operations, or other financial results; statements with respect to the plans, strategies and objectives of management for future operations; statements concerning product research, development and commercialization plans, timelines and anticipated results; our capital needs and capital expenditures; our and our collaborators market position and competitive changes in the marketplace for our and our collaborators products; our ability to innovate new products and technologies; intellectual property and litigation matters; potential acquisitions and divestitures; key personnel; statements of expectation or belief; the effect of new accounting pronouncements and other characterizations of future events or circumstances; and statements of assumptions underlying any of the foregoing are forward-looking statements.

Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make due to a number of important factors, including:

  • risks and uncertainties inherent in medical device research and development, such as those related to our and our collaborators ability to successfully develop, test and gain approval of our product candidates;
  • our and our collaborators ability to complete the development of our drug candidates under the timelines we anticipate in current and future clinical trials;
  • our and our collaborators ability to obtain, maintain and enforce intellectual property rights and to obtain freedom to operate under third party intellectual property;
  • competition;
  • our and our collaborators ability to establish and maintain suitable manufacturing arrangements for drug candidates;
  • Our ability to identify, enter into and maintain collaboration agreements with appropriate third-parties;
  • our ability to obtain necessary financing;
  • the potential impact of adverse economic and market conditions;
  • our and our collaborators ability to successfully execute on our strategic plans; and
  • other risk factors discussed under the caption "Risk Factors" and elsewhere in our most recent filings with the Securities and Exchange Commission including without limitation our most recent Annual Report on Form 10-K, our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K.

Any forward-looking statements contained in this presentation speak only as of the date hereof, and we expressly disclaim any obligation to update any forward-looking statements except to the extent required by law.